Randeep Sangha - Department of Medical Oncology, Cross Cancer Institute

基本信息

浏览量：88

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 87 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

A First-in-human, Open-Label, Phase I Trial of Daily Oral Zelenirstat, an NMT Inhibitor, in Patients with Relapsed/refractory Advanced Cancer Including Gastrointestinal Cancers

Jennifer L. Spratlin,Randeep S. Sangha,Rahima Jamal,Erwan Beauchamp,Luc G. Berthiaume,John Robert Mackey

Journal of Clinical Oncologyno. 3_suppl (2024): 129-129

引用0浏览0引用

Zelenirstat Nmt Inhibitor in Patients with Relapsed/Refractory B-Cell Lymphoma and Acute Myelogenous Leukemia: Mechanistic Insights and Clinical Outcomes

Randeep Sangha,John Kuruvilla,Laurie H. Sehn,Michael Weickert,Erwan Beauchamp, Jay M. Gamma,Naveen Pemmaraju,Gautam Borthakur,Luc G. Berthiaume,John R. Mackey

BLOOD（2024）

引用0浏览0引用

Real-World Treatment Patterns, Health Outcomes, and Healthcare Resource Use in Advanced Common EGFR-Positive Non-Small Cell Lung Cancer Patients Treated with Osimertinib in Alberta

Winson Y. Cheung,Chantelle Carbonell,Vishal Navani,Randeep S. Sangha,Emmanuel M. Ewara,Julia Elia-Pacitti, Sandra Iczkovitz,Tamer N. Jarada,Matthew T. Warkentin

Current oncology (Toronto, Ont)no. 8 (2024): 4382-4396

引用0浏览0WOS引用

Sarah Cook, Vanessa Samuel,Daniel E. Meyers,Igor Stukalin, Ishjot Litt,Randeep Sangha,Don G. Morris,Daniel Y. C. Heng,Aliyah Pabani,Michelle Dean,Vishal Navani

JAMA NETWORK OPEN（2024）

引用23浏览0WOS引用

Abstract CT194: N-myristoylation Inhibitor Zelenirstat: New Mechanistic Insights and Efficacy Signals from a First in Human Phase I Study

Luc Gerard Berthiaume,Erwan Beauchamp,Jay Gamma,Rony Pain,Morris A. Kostiuk,Christopher R. Cromwell,Eman W. Moussa,Olivier Julien,Basil P. Hubbard,John Kuruvilla,Laurie H. Sehn,Jennifer Spratlin,Rahima Jamal,Randeep Sangha,John R. Mackey

Cancer Researchno. 7_Supplement (2024): CT194-CT194

引用1浏览0引用

A First-in-human Phase I Trial of Daily Oral Zelenirstat, a N-myristoyltransferase Inhibitor, in Patients with Advanced Solid Tumors and Relapsed/refractory B-cell Lymphomas

Randeep Sangha,Rahima Jamal,Jennifer Spratlin,John Kuruvilla,Laurie H. Sehn,Erwan Beauchamp,Michael Weickert,Luc G. Berthiaume,John R. Mackey

Journal of Clinical Oncology（2024）

引用2浏览0WOS引用

Supplementary Figure 4 from Phase I Trials of Anti-ENPP3 Antibody–Drug Conjugates in Advanced Refractory Renal Cell Carcinomas

John A. Thompson,Robert J. Motzer,Ana M. Molina,Toni K. Choueiri,Elisabeth I. Heath,Bruce G. Redman,Randeep S. Sangha,D. Scott Ernst,Roberto Pili,Stella K. Kim,Leonard Reyno,Aya Wiseman,Fabio Trave,Banmeet Anand,Karen Morrison,Fernando Doñate,Christian K. Kollmannsberger

openalex（2023）

引用0浏览0引用

Supplementary Figure 6 from Phase I Trials of Anti-ENPP3 Antibody–Drug Conjugates in Advanced Refractory Renal Cell Carcinomas

crossref（2023）

引用0浏览0引用

A First-in-human, Open-Label, Phase I Trial of Daily Oral PCLX-001, an NMT Inhibitor, in Patients with Relapsed/refractory B-cell Lymphomas and Advanced Solid Tumors

Randeep S. Sangha,Rahima Jamal,Jennifer L. Spratlin,John Kuruvilla,Laurie Helen Sehn,Michael Weickert,Luc G. Berthiaume,John Robert Mackey

JOURNAL OF CLINICAL ONCOLOGYno. 16 (2023)

引用0浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn